Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis

Author： Nebuloni  

Publisher： Spandidos Publications

ISSN： 2049-9469

Source： Molecular and Clinical Oncology, Vol.1, Iss.1, 2013-01, pp. : 175-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a firstline treatment for Japanese patients with metastatic colorectal cancer

By                    

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 134-138

Spandidos Publications

Access to resources Recommend Favorite

Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation

By Keown P.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 1140-1141

Elsevier

Access to resources Recommend Favorite

Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 1182-1188

Spandidos Publications

Access to resources Recommend Favorite

Move More, Sit Less: A First-Line, Public Health Preventive Strategy?

By Franklin Barry A.   Brinks Jenna   Sternburgh Lucy  

Preventive Cardiology, Vol. 13, Iss. 4, 2010-0 ,pp. : 203-208

Blackwell Publishing

Access to resources Recommend Favorite

Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the firstline treatment of metastatic colorectal cancer

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 166-170

Spandidos Publications

Access to resources Recommend Favorite